

Subject Index 2009

- adjuvant therapy: 4/274-281
 advanced disease: 1/41-46
 alkaline comet assay: 2/97-107
 angiosarcoma: 2/126-131

 barium-enema: 1/26-29
 bleomycin: 4/264-273
 blood parameters: 4/282-292
 bone metastases: 4/213-224
 brain stem multiple infarcts: 3/170-174
 bronchial artery: 3/152-161
 Budd-Chiari syndrome: 4/225-232

 cancer cachexia: 2/65-75
 cell size measurements: 2/108-119
 cell swelling: 2/108-119
 cervical cancer: 4/293-298
 chemotherapy: 1/1-8
 cholecystitis: 2/76-83
 chondrosarcoma: 3/187-194
 cisplatin: 2/120-125; 4/264-273
 color Doppler sonography: 4/225-232
 colorectal carcinoma: 4/264-273
 complex aneurysm: 4/233-239
 complications of treatment: 2/84-87
 computed tomography: 4/247-257
 computed tomography segmentation:
 3/180-186
 concomitant chemoradiotherapy: 4/293-
 298
 CT: 3/137-143
 cyst: 3/162-169
 cytokines: 2/65-75

 deep dorsal vein: 1/17-25
 diagnostics: 1/47-53
 diffusion test: 2/97-107
 dose distribution: 1/56-64
 dose-volume histograms: 2/132-135
 dual modality imaging: 3/180-186

 electrochemotherapy: 3/195-202; 4/264-273
 electrofusion: 2/108-119
 electroporation: 2/108-119; 4/264-273
 embolization: 3/152-161; 1/17-25

 FDG: 4/258-263
 fluorine-18-fluorodeoxyglucose: 4/258-263
 follow-up: 4/258-263; 4/247-257
 forward planned IMRT: 1/56-64
 Fpg-modified comet assay: 2/97-107
 fracture of vertebrae: 3/170-174

 gallbladder: 2/76-83
 gallbladder carcinoma: 2/126-131
 gamma radiation: 2/97-107
 gastric cancer: 4/274-281
 Gaussian and Fermi statistics: 2/132-135
 Glut-1: 3/195-202
 gross tumor volume: 2/132-135

 helical tomotherapy: 3/203-212
 hepatitis C: 2/84-87
 history: 3/137-143
 Hodgkin s disease: 4/258-263
 human peripheral blood lymphocytes:
 2/97-107

- hydatid: 3/162-169
 hypotonic treatment: 2/108-119
 hypoxia: 3/195-202
- image registration: 3/203-212
 interferon: 2/84-87
 interventional radiology: 3/137-143
 intracranial stent: 4/233-239
 intraoral cancer: 4/282-292
- KRAS: 1/1-8
- late toxicity: 2/88-96
 limb-sparing: 3/187-194
 lipiodol: 1/17-25
 liver: 2/126-131
 liver fibrosis: 1/30-40
 liver hydatid disease: 4/225-232
 locally recurrent - rectal cancer: 3/144-151
 lung cancer: 1/47-53
- magnetic resonance imaging: 4/247-257;
 4/240-246
 massive haemoptysis: 3/152-161
 mesothelioma: 1/9-16
 metastasis: 3/175-179
 metastatic colorectal cancer: 1/1-8
 Moringa oleifera: 1/30-40
 MRI: 3/137-143; 1/30-40
 multi-modality therapy: 3/144-151
 muscle: 2/65-75
 muscle wasting: 2/65-75
 myasthenia gravis: 3/170-174
- nasopharyngeal carcinoma: 4/247-257
 n-Butyl-2-cyanoacrylate: 1/17-25
 negative predictive value: 4/258-263
- neo-adjuvant chemotherapy: 3/187-194
 neurotoxicity: 2/120-125
- palliative treatment: 4/213-224
 patient positioning: 3/203-212
 penile cancer: 1/41-46
 PET: 4/258-263
 PET/CT: 3/180-186
 pimonidazole: 3/195-202
 pineal gland: 3/175-179
 positron emission tomography: 4/247-257
 posterior reversible encephalopathy
 syndrome: 2/120-125
 postoperative radiotherapy: 2/88-96
 prognosis: 4/258-263
 prostate cancer: 2/88-96
 prostate radiotherapy: 3/203-212; 1/56-64
- quality of life: 4/293-298
- radiochemotherapy: 4/274-281
 radiology: 3/137-143
 radiotherapy: 4/213-224; 4/282-292; 1/41-
 46
 radiotherapy toxicity: 2/126-131
 rectal perforation: 1/26-29
 recurrence: 3/162-169
 regulatory volume decrease: 2/108-119
 ribavirin: 2/84-87
 ROS: 2/97-107
- sigmoid colon shielding: 1/56-64
 simian virus 40: 1/9-16
 squamous cell carcinoma: 3/175-179
 stent migration: 4/233-239
 subdural haematoma: 2/84-87
 surgery: 4/282-292; 4/240-246
 survival: 4/274-281; 1/47-53

T antigen: 1/9-16
targeted therapy: 1/1-8
texture analysis: 1/30-40
therapy: 1/47-53
therapy monitoring: 4/258-263
toxicity: 4/274-281

ultrasound: 3/137-143

venous impotence: 1/17-25
vertebral osteomyelitis: 4/240-246
viability: 2/108-119
viral carcinogenesis: 1/9-16
von Willebrand disease: 2/84-87

whole pelvic irradiation: 1/56-64
whole pelvic radiotherapy: 2/88-96

xanthogranulomatous: 2/76-83